scholarly journals P185 Experience of using high flow nasal oxygen first line to treat hypoxemic respiratory failure due to COVID 19 in patients in whom critical care admission was felt to be not of benefit on a respiratory support unit (RSU) from October 2020 to March 2021

2021 ◽  
Author(s):  
DA Tarpey ◽  
S Woods ◽  
S Jain
Keyword(s):  
Critical Care ◽  
Respiratory Failure ◽  
High Flow ◽  
Respiratory Support ◽  
First Line ◽  
Hypoxemic Respiratory Failure ◽  
Support Unit ◽  
Critical Care Admission

scholarly journals FIRST-line support for assistance in breathing in children (FIRST-ABC): a master protocol of two randomised trials to evaluate the non-inferiority of high-flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care

BMJ Open ◽  
2020 ◽  
Vol 10 (8) ◽  
pp. e038002 ◽  
Author(s):  
Alvin Richards-Belle ◽  
Peter Davis ◽  
Laura Drikite ◽  
Richard Feltbower ◽  
Richard Grieve ◽  
...  
Keyword(s):  
Critical Care ◽  
Continuous Positive Airway Pressure ◽  
Airway Pressure ◽  
Positive Airway Pressure ◽  
High Flow ◽  
Respiratory Support ◽  
High Flow Nasal Cannula ◽  
First Line ◽  
Non Invasive ◽  
Paediatric Critical Care

IntroductionEven though respiratory support is a common intervention in paediatric critical care, there is no randomised controlled trial (RCT) evidence regarding the effectiveness of two commonly used modes of non-invasive respiratory support (NRS), continuous positive airway pressure (CPAP) and high-flow nasal cannula therapy (HFNC). FIRST-line support for assistance in breathing in children is a master protocol of two pragmatic non-inferiority RCTs to evaluate the clinical and cost-effectiveness of HFNC (compared with CPAP) as the first-line mode of support in critically ill children.Methods and analysisWe will recruit participants over a 30-month period at 25 UK paediatric critical care units (paediatric intensive care units/high-dependency units). Patients are eligible if admitted/accepted for admission, aged >36 weeks corrected gestational age and <16 years, and assessed by the treating clinician to require NRS for an acute illness (step-up RCT) or within 72 hours of extubation following a period of invasive ventilation (step-down RCT). Due to the emergency nature of the treatment, written informed consent will be deferred to after randomisation. Randomisation will occur 1:1 to CPAP or HFNC, stratified by site and age (<12 vs ≥12 months). The primary outcome is time to liberation from respiratory support for a continuous period of 48 hours. A total sample size of 600 patients in each RCT will provide 90% power with a type I error rate of 2.5% (one sided) to exclude the prespecified non-inferiority margin of HR of 0.75. Primary analyses will be undertaken separately in each RCT in both the intention-to-treat and per-protocol populations.Ethics and disseminationThis master protocol received favourable ethical opinion from National Health Service East of England—Cambridge South Research Ethics Committee (reference: 19/EE/0185) and approval from the Health Research Authority (reference: 260536). Results will be disseminated via publications in peer-reviewed medical journals and presentations at national and international conferences.Trial registration numberISRCTN60048867

Is high-flow nasal cannula oxygenation more effective than noninvasive ventilation or conventional oxygen therapy in treating acute hypoxemic respiratory failure in COVID-19 patients?

2020 ◽  
Vol 54 ◽  
Author(s):  
Cary Amiel G. Villanueva ◽  
Marie Gene D. Cruz ◽  
Lia M. Palileo-Villanueva
Keyword(s):  
Respiratory Failure ◽  
Noninvasive Ventilation ◽  
Observational Studies ◽  
Oxygen Therapy ◽  
High Flow ◽  
Nasal Cannula ◽  
Respiratory Support ◽  
High Flow Nasal Cannula ◽  
Hypoxemic Respiratory Failure ◽  
Acute Hypoxemic Respiratory Failure

KEY FINDINGSVery low-quality evidence suggests lower mortality (based on five observational studies) but higher failurerate of respiratory support (based on two observational studies) in COVID-19 patients given high-flow nasalcannula (HFNC) oxygen compared with noninvasive ventilation (NIV) and conventional oxygenation therapy.Randomized controlled trials (RCT) are urgently needed in this area.• Respiratory failure accounts for about half of deaths in patients with COVID-19.• High-flow nasal cannula (HFNC) oxygen therapy reduces the need for escalating respiratory support and improvespatient comfort compared with conventional oxygen therapy among those with acute respiratory failure.• Mortality was consistently lower in COVID-19 patients who received HFNC rather than NIV or conventionaloxygen therapy (COT) across 5 very low-quality retrospective observational studies from China.• Several international guidelines recommend the use of HFNC oxygen therapy in COVID-19 patients whodevelop acute hypoxemic respiratory failure. However, local guidelines from the Philippine Society forMicrobiology and Infectious Diseases (PSMID) and the Philippine College of Chest Physicians (PCCP) recommendagainst HFNC due to risks of transmission and paucity of direct evidence for efficacy.• Additional infection control precautions, i.e. wearing a surgical mask over the cannula, and locating in a negativepressure room, are recommended whenever using HFNC or NIV.• There are at least two ongoing trials due to be completed by the second quarter of 2021 comparingHFNC oxygenation with NIV or COT in COVID-19 patients.

scholarly journals High Flow Nasal Cannula Oxygen In Non-Critical Care Units In Patients Infected With SARS-CoV-2 Who Are Not Suitable For Intensive Care Unit

2021 ◽  
Author(s):  
Laura Bouetard ◽  
Dorothée Vignes ◽  
Dorra Braham ◽  
Raluca Sterpu ◽  
Charles Damoisel ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Critical Care ◽  
Intensive Care ◽  
Respiratory Failure ◽  
High Flow ◽  
Nasal Cannula ◽  
High Flow Nasal Cannula ◽  
Hypoxemic Respiratory Failure ◽  
Old Patients ◽  
Improve Patient Survival

Abstract Background:High-flow nasal cannula (HFNC) is a recent respiratory support technique used for patients with hypoxemic respiratory failure; its use usually takes place in critical care wards. During the second wave of Covid-19, almost 400 000 people were hospitalized in France, and intensive care units were overwhelmed. For patients who did not meet criteria for admission to an intensive care unit because of their age or their medical background, we proposed HFNC in non-critical care unit instead of standard oxygen therapy to improve patient survival and comfort.Objectives: To describe characteristics and outcomes of patients infected with SARS-CoV-2 with HFNC in non-critical care wards between September 2020 and June 2021.Methods: This was a single-center, retrospective cohort study conducted between September and June 2021 in Clamart Hospital, France. Patients infected with SARS-CoV-2 confirmed, who were not suitable for intensive care unit escalation, and who were proposed HFNC because of respiratory failure were assessed.Results:Thirty-one patients with SARS-CoV-2 were included, median age 87.0 years (interquartile range (IQR), 82.0-91.0), 52% men. Nineteen (61%) patients were OMS score 0, i.e. no disability in daily-life activities. HNFC was started a median of 3 days (IQR, 1-5.5) after hospitalization. Overall, median duration of HNFC was 6 days (IQR, 4-10). Eleven patients (35.5%) survived and were discharged from hospital.Conclusions:Our experience of HFNC for patients with COVID-19 outside of a critical care environment because of their age and comorbidities is positive allowing survival of 35% of old patients not admitted to an intensive care unit. Trial registration:Not applicable

Sign in / Sign up

Export Citation Format

Share Document